Cancer Therapy AdvisorLEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab

Lead author of the study, Dr. Ana Maria Arance, who presented the results over the summer at the ASCO Annual Meeting, commented: “With additional follow-up, lenvatinib plus pembrolizumab continues to show clinically meaningful, durable responses in patients with advanced melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given alone or in combination. These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need.”